Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, has been invited to present at the CHI’s 8th Annual Immuno-Oncology Summit Europe from April 23-25, 2024, in London, UK, as well as at the 7th International Neoantigen Summit to be held in Amsterdam, Netherlands from April 29 – May 1, 2024.
Medigene to Present at Upcoming Scientific Conferences
Campinas (LabNews Media LLC) – Flour from the brown alga Sargassum filipendula can significantly increase the nutrient density and digestibility of gluten-free cookies. Even an addition of just…
Miami (LabNews Media LLC) – A previously unknown, sex-specific immune mechanism could improve the treatment of the aggressive brain tumor glioblastoma in women in the future. Researchers from Sylvester Comprehensive…
Los Angeles (LabNews Media LLC) – A low-protein diet enriched with the amino acid methionine can extend healthy lifespan in mice, reduce fat mass…
